Maria Cavaller-Bellaubi

Sustaining Meaningful Patient Engagement Across the Lifecycle of Medicines: A Roadmap for Action

Maria Cavaller-Bellaubi, Stuart Faulkner, Bryan Teixeira et al. · Therapeutic Innovation & Regulatory Science · 2021 · 52 citations · Full text

Public Affairs, Health Policy, Pharmaceutical Policy +16

Drug repurposing for rare: progress and opportunities for the rare disease community

Anneliene Hechtelt Jonker, Daniel O’Connor, Maria Cavaller-Bellaubi et al. · Frontiers in Medicine · 2024 · 45 citations · Full text

Pharmacy, Health Informatics, Pharmacology +13

Paediatric Inflammatory Bowel Disease: A Multi-Stakeholder Perspective to Improve Development of Drugs for Children and Adolescents

Nicholas M. Croft, Lissy de Ridder, Anne M. Griffiths et al. · Journal of Crohn s and Colitis · 2022 · 38 citations · Full text

Pharmacy, Pediatrics, Pharmacology +17

The European Medicines Agency facilitates access to medicines in low- and middle-income countries

Maria Cavaller-Bellaubi, Martin Harvey Allchurch, Clement Lagalice et al. · Expert Review of Clinical Pharmacology · 2020 · 25 citations · Full text

Pharmacy, Pharmaceutical Policy, Drug Approval Processes +12

Patients, payers and developers of Orphan Medicinal Products: lessons learned from 10 years’ multi-stakeholder dialogue on improving access in Europe via MoCA

Maria Cavaller-Bellaubi, Wills Hughes-Wilson, Šárka Kubinová et al. · Orphanet Journal of Rare Diseases · 2023 · 10 citations · Full text

Public Affairs, Health Policy, Pharmaceutical Policy +17